


 Cite this: *RSC Adv.*, 2021, 11, 13885

Synthesis and conversion of primary and secondary 2-aminoestradiols into A-ring-integrated benzoxazolone hybrids and their *in vitro* anticancer activity†‡

 Ferenc Kovács,^a Mohana K. Gopisetty,^b Dóra I. Adamecz,^b Mónika Kiricsi,^b Éva A. Enyedy^{cd} and Éva Frank^{id*^a}

Hybrid systems are often endowed with completely different and improved properties compared to their parent compounds. In order to extend the chemical space toward sterane-based molecular hybrids, a number of estradiol-derived benzoxazol-2-ones with combined aromatic rings were synthesized *via* the corresponding 2-aminophenol intermediates. 2-Aminoestradiol was first prepared from estrone by a two-step nitration/reduction sequence under mild reaction conditions. Subsequent reductive aminations with different arylaldehydes furnished secondary 2-aminoestradiol derivatives in good yields. The proton dissociation processes of the aminoestradiols were investigated in aqueous solution by UV-visible spectrophotometric titrations to reveal their actual chemical forms at physiological pH. The determined pK_1 and pK_2 values are attributed to the $^+NH_3$ or $^+NH_2R$ and OH moieties, and both varied by the different R substituents of the amino group. Primary and secondary 2-aminoestradiols were next reacted with carbonyldiimidazole as a phosgene equivalent to introduce a carbonyl group with simultaneous ring-closure to give A-ring-fused oxazolone derivatives in high yields. The novel aminoestradiols and benzoxazolones were subjected to *in vitro* cytotoxicity analysis and were found to exert cancer cell specific activity.

 Received 10th March 2021
Accepted 5th April 2021

DOI: 10.1039/d1ra01889b

rsc.li/rsc-advances

Introduction

Molecular hybridization is a very promising approach in drug design and can offer therapeutic options for a wide variety of diseases.^{1,2} The main goal of hybrid development is to enhance or favourably modulate the pharmacokinetic and/or pharmacodynamic properties of a molecule through the synergistic effects of combined structural elements; although combating multidrug resistance and minimizing unwanted side effects are also important considerations. Occasionally, new, unpredictable bioactivities may arise which are different from those of the individual molecules that constitute the hybrid compounds.^{3,4}

Thanks to their attractive structural, physicochemical and biological features, natural sex steroids are often used to construct molecular hybrids for anticancer indication,^{5–7} either by covalent attachment to another pharmacophore directly⁸ or *via* a spacer,⁹ or by integrating key functional elements to form a new chemical entity.¹⁰ However, any residual hormonal effect of the steroid moiety is undesirable in these cases, and should be significantly reduced or, preferably, eliminated during hybrid formation.

For estrane-based hybrids, the best way to avoid hormonal side effects is to modify the OH groups at positions C-3 and C-17, which are primarily responsible for the hormone receptor binding *via* H-bonding interactions.¹¹ Decreased affinity to the target protein, due to electronic and steric reasons, has also been demonstrated for a number of 2-substituted estradiol derivatives (*e.g.*, 2-methoxyestradiol), which, however, are effective in inhibiting the proliferation of various human cancer cells.^{12–16} Although the cytotoxic effect of 2-nitroestradiol obtained by direct nitration of estradiol was weaker than that of 2-methoxyestradiol, the attachment of a piperidine or morpholine ring to the phenolic-O through a spacer led to particularly potent cytotoxic compounds.¹⁷ Interestingly, there are very few examples in the literature for the preparation of A-ring-modified estrane-based derivatives containing a [2,3]-fused heterocyclic

^aDepartment of Organic Chemistry, University of Szeged, Dóm tér 8, H-6720 Szeged, Hungary. E-mail: frank@chem.u-szeged.hu; Tel: +36-62-544-275

^bDepartment of Biochemistry and Molecular Biology, Doctoral School of Biology, University of Szeged, Közép fasor 52, H-6726 Szeged, Hungary

^cDepartment of Inorganic and Analytical Chemistry, Interdisciplinary Excellence Centre, University of Szeged, Dóm tér 7, H-6720 Szeged, Hungary

^dMTA-SZTE Lendület Functional Metal Complexes Research Group, University of Szeged, Dóm tér 7, H-6720 Szeged, Hungary

† Dedicated to Prof. Gyula Schneider on his upcoming 90th birthday.

‡ Electronic supplementary information (ESI) available. See DOI: 10.1039/d1ra01889b



moiety.^{18,19} Elimination of the phenolic OH group in parallel with the substitution at C-2 makes it even more likely that the compound will not be able to bind to hormone receptors, and possibly other major bioactivities can predominate without undesired side effects.

Since 2-aminophenols are valuable building blocks for many biologically active compounds²⁰ and can be used as starting materials for the synthesis of pharmacologically important N,O-heterocycles,^{21–23} our primary aim was to introduce an amino substituent at the C-2 position of estradiol. In view of the high reactivity of the phenolic A-ring of estrogens toward electrophiles and the two available *ortho* positions (C-2 and C-4), the regioselective introduction of a substituent into C-2 that can be easily converted to an amino group is a challenging task. Although C-2 attack is slightly favoured, in most of the cases, *e.g.* during halogenation, nitration or formylation, mixtures of mono- and disubstituted products – which are often difficult to separate – were usually obtained, and the yield of the 2-functionalized derivative was only moderate.²⁴ Accordingly, the first step of the seemingly simplest process involving nitration and subsequent reduction for the synthesis of primary 2-amino estradiol often suffered from the above-mentioned problems.^{25,26}

When forming a 2-aminophenol moiety on estrogens, given the high cost of sex hormones, it is desirable to develop a process that consists of only few reaction steps and provides the product in acceptable yield. Moreover, if the amino derivative is to be used as a starting material for the preparation of N,O-heterocycles, it must be synthesized in a reproducible manner in larger quantities. Although the task does not seem difficult from an organic chemical point of view, it is no coincidence that there are only few literature examples for the preparation of 2-aminoestrone or 2-aminoestradiol, most of which are based on a two-step procedure, *i.e.* nitration and subsequent reduction after separation of the mono- and dinitro

derivatives^{26–30} (Fig. 1B). All other synthetic methods, *e.g.* those depicted in Fig. 1A^{31–36} and Fig. 1C,^{37,38} involve several steps and require protection/deprotection of the phenolic OH group, expensive reagents or harsh conditions, and suffer from selectivity problems that ultimately lead to the final product in lower yields than route B.

In addition to studying a number of methods that may be suitable for the most efficient and scalable access to 2-aminoestradiol, our next goal was to further convert the compound to secondary aminophenols by reductive amination. In order to characterize the actual chemical forms (and charges) of the novel compounds in solution focusing on physiological pH, and to explore the effect of the various substituents on the aromatic ring of the benzylamino moiety in the case of secondary amines, the proton dissociation constants (K_a) of the amphoteric aminophenols were determined by UV-visible spectrophotometric titrations. Finally, bifunctional derivatives were subjected to CDI-induced ring-closure reactions with the simultaneous incorporation of a carbonyl group from the reagent to furnish various novel estradiol-benzoxazolone molecular hybrids. The cytotoxicity of all synthesized derivatives was tested *in vitro* by the colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay using human MCF-7 breast, HeLa cervical as well as DU145 and PC-3 prostate cancer cell lines, and simultaneously non-cancerous MRC-5 fibroblast cells. Based on the primary toxicity screen, five potent compounds were selected and subjected to further experiments to obtain their IC_{50} values on different cell lines.

Result and discussion

Synthetic studies

Based on the literature background, we selected the two-step method for the preparation of 2-aminoestradiol; however, both the nitration of estrone and the following reduction were




Fig. 1 Possible routes for the synthesis of 2-amino estrogens.

investigated separately. Since mononitration seemed unavoidable at both the C-2 and C-4 positions of the sterane core, we tried to find a proper experimental condition where at least over-nitration and thus the formation of the dinitro product could be eliminated. A number of literature procedures describing the selective mononitration of phenol or estrone either by using 65% (m/m) HNO₃²⁹ or metal nitrates²⁸ were tried to be reproduced in different solvents (such as AcOH, dioxane, EtOH, CH₂Cl₂ or CHCl₃), however, significant amount of 2,4-dinitro derivative reducing the yield of the desired product, was obtained in all cases. Furthermore, unreacted estrone remained in the reaction mixtures when the nitrating agent was not used in excess, which further complicated the separation and purification process.

Since the selective nitration of phenol and substituted phenols to the corresponding mononitro compounds was reported earlier under mild conditions in a liquid-liquid two-phase system with diluted nitric acid (6% m/m) and in the presence of tetrabutylammonium bromide as phase-transfer catalyst,³⁹ we tried to adapt this method on the substitution reaction of estrone (**1**). However, given the poor solubility of estrone relative to phenol in water-immiscible organic solvents, a relatively large amount had to be used to prepare a homogeneous solution, so that the volume of water (added with a diluted HNO₃ solution) was significantly smaller than that of the organic phase. Therefore, a phase transfer catalyst was not required even during the scale-up synthesis; the reaction proceeded with 1 equiv. of nitrating reagent in boiling CH₂Cl₂ under vigorous stirring for 1 h to give exclusively a *ca.* 1 : 1 mixture of 2- and 4-nitroestrone in 92% overall yield (Scheme 1). The mononitro derivatives were easily separated by column chromatography owing to their large polarity difference. First, 2-nitroestrone (**2**) eluted from the column; its more apolar nature is due to the intramolecular hydrogen bonding interaction between the phenolic OH and the NO₂ group. In contrast, the more polar character of 4-nitroestrone (**3**) can be attributed to the fact that due to its sterically hindered environment, the nitro group twists out of the plane of the sterane skeleton,⁴⁰ therefore, intramolecular interaction masking the polarity of the functional groups cannot develop.

Although mononitration was not regioselective, both successfully separated nitro compounds (**2** and **3**) subsequently


proved to be suitable, after reduction, for the synthesis of A-ring [2,3]-fused and [3,4]-fused 2-oxazolones.

As a continuation, conversion of **2** and **3** to aminoestradiols was investigated. An insoluble red precipitate was formed as a by-product when 2-nitrophenols (**2** or **3**) were reduced with iron filings under classical Béchamp conditions, probably due to metal complex formation, and then complex dissociation by adding NaOH was also unsuccessful thanks to the high susceptibility of sodium phenolates to oxidation. Therefore, another hydrogenation method had to be found. In order to avoid introducing flammable hydrogen into the reaction mixture from a gas cylinder, hydrogen generated *in situ* from NaBH₄ in a protic solvent (MeOH) in the presence of Pd-C^{41,42} was used for catalytic reduction of **2** and **3** (Scheme 1). This method was also suitable to reduce not only the NO₂ but also the 17-(C=O) group stereoselectively, thus resulting in 2- (**4**) or 4-aminoestradiol (**6**) in a single step with excellent isolated yields. In view of the amphoteric character of the products, adjustment of neutral pH during work-up was of crucial importance.


In the following, unsubstituted (**8a**) and *para*-substituted benzylamino estradiols (**8b-h**) were prepared from **4** with benzaldehyde and its derivatives by reductive amination (Table 1). Imine formation was performed in the presence of a catalytic amount of AcOH and molecular sieves by boiling the reactants in MeOH for 1 h. Secondary aminophenols (**8a-h**) were obtained in good to excellent yields by reducing the unstable imines *in situ* with NaBH₄. With the only exception of the *p*-nitro-substituted compound (**8f**), all derivatives were found to be stable both in the solid state and in organic solvents (Table 1).

Both the prepared primary (**4** and **6**) and secondary amines (**8a-h**) were further converted to estradiol-benzoxazolone hybrids by cyclization and incorporation of a carbonyl group from the applied 1,1-carbonyldiimidazole (CDI) reagent in the presence of triethylamine (TEA) as base by boiling in THF (Scheme 1 and Table 1). The reactions provided the products (**5**, **7** and **9a-h**) in good yield (67–94%) within 2 h.

The structures of all compounds prepared in our experimental work were confirmed by ¹H and ¹³C NMR spectroscopic and high-resolution electrospray ionization mass spectrometry (ESI-HRMS) methods. Due to the nature of the transformations



Scheme 1 Two-step synthesis of monoamino-estradiol regioisomers and their conversion to A-ring-fused 2-oxazolones.

Table 1 Synthesis of secondary aminoestradiols by reductive amination and their conversion to A-ring-fused *N*-substituted 2-oxazolones

Entry	R	Aminoestradiol	Yield ^a (%)	Benzoxazolone	Yield ^a (%)
1	H	8a	76	9a	69
2	F	8b	76	9b	76
3	Cl	8c	91	9c	94
4	Br	8d	75	9d	77
5	CN	8e	96	9e	92
6	NO ₂	8f	82 ^b	9f	92
7	CH ₃	8g	72	9g	78
8	OMe	8h	94	9h	90

^a After purification by column chromatography. ^b Proved to be sensitive to oxidation even in the solid state.

performed, the range of ¹H NMR spectra above chemical shift values of 3 ppm was informative; below 3 ppm, the signals of the skeletal protons and the C-13 angular methyl group could be observed. The most important difference between 2- and 4-nitroestrone (2, 3) and 2- and 4-aminoestradiol (4, 6) derivatives can be noticed in the aromatic range of the ¹H NMR spectra. For the 2,3-disubstituted compounds (2, 4), the C-1 and C-4 protons give singlet signals, while the adjacent C-1 and C-2 protons of the 3,4-disubstituted analogs (3, 6) appear as doublets with the same coupling constant. In the spectra of the secondary aminophenols (8), the appearance of the extra signals between 7 and 8 ppm as well as the presence of the benzyl-CH₂ at 4.3 ppm are indicative for the incorporation of the aromatic ring from the arylaldehyde reagents and the success of the reductive amination. As for the oxazolone (5, 7, 9) derivatives, the negative carbon signal of the introduced C=O group can be seen at around 154 ppm in the ¹³C NMR spectra (J-MOD), which indicated the heterocyclization of the aminophenols upon treatment with CDI.

Proton dissociation processes of primary and secondary aminoestradiols

The methods (NMR, ESI-HRMS) used for the characterization of 2-aminoestradiols (4 and 8a–h) provide information about their purity and chemical structure in the solid phase and in solution of organic solvents. However, knowledge on their behaviour in aqueous solution and proton dissociation is essential for a deeper understanding of their pharmacological properties and structure–activity relationships. Therefore, we aimed to determine the proton dissociation constants (*K*_a) of the compounds to predict their actual chemical forms at pH 7.4 in solution, and to reveal the influence of the various substituents. The studied sterane-based derivatives (4 and 8a–h) have limited solubility in pure water, thus UV-visible spectrophotometric titrations were performed on samples containing 50 μM

compound in a 30% (v/v) DMSO/H₂O solvent mixture. However, the halogen and CN substituents in 8b–e resulted in worse solubility, and lower compound concentration (10 μM) had to be applied to avoid the appearance of precipitate. Since 2-aminophenol (2AP) and its derivatives can easily undergo oxidation, especially in their completely deprotonated forms,^{43,44} a strong argon flow was applied during the titrations to exclude the oxygen. Deprotonation processes of 2AP as a simpler model




Fig. 2 (a) UV-visible spectra recorded for 4 at various pH values. (b) Concentration distribution curves calculated for 4 and the measured absorbance values at 310 nm (●) with the fitted values (blue solid line). (c = 50 μM; l = 2 cm; 30% (v/v) DMSO/H₂O; T = 25 °C; I = 0.1 M (KCl)).

compound were also investigated for comparison. The studied compounds displayed strong absorption bands in the UV region mostly due to π - π^* transitions of the benzene rings. Representative UV-visible spectra recorded for **4** at various pH values are shown in Fig. 2a. Two well-separated processes can be observed upon increasing the pH; namely, the first step is accompanied by an increase of the absorbance and the λ_{max} from 282 nm to 296 nm in the pH range from 2 to 7, while the second deprotonation step, taking place at pH > 9.5 results in a further increase in the λ_{max} (310 nm) with the appearance of a novel band in the wavelength range 350–470 nm. As the deprotonation steps are not overlapping, clear-cut isosbestic points could be found at 284 nm and 302 nm in case of the $\text{H}_2\text{L}^+ \rightleftharpoons \text{HL} + \text{H}^+$ and $\text{HL} \rightleftharpoons \text{L}^- + \text{H}^+$ equilibrium processes, respectively, where L^- is the completely deprotonated form of the compound. This finding also indicates that no disturbing processes such as oxidation took place during the titration of **4** under the flow of the inert gas. Proton dissociation constants (K_a) were determined by the deconvolution of the measured spectra and are collected in Table 2.

Based on the determined $\text{p}K_a$ values, concentration distribution curves were computed (Fig. 2b) showing the predominant formation of the HL species in the pH range *ca.* 6–9.5. The $\text{p}K_a$ values were also determined for **2AP** and sterane-based compounds based on the recorded spectra (Table 2, see representative spectra and concentration distribution curves for **8a** in Fig. 3). Notably, the spectra recorded for the compounds with the methoxy (**8h**), nitrile (**8e**), chlorine (**8c**) and bromine substituents (**8d**) showed a certain extent of oxidation in the basic pH range (as no clear isosbestic point was found at pH > 10); therefore, the $\text{p}K_2$ values could not be determined accurately.

Similarly to the case of **2AP**,⁴⁵ the $\text{p}K_1$ values are attributed to the amino moiety (NH_3^+ or NH_2^+) in all cases, while the $\text{p}K_2$ values belong to the phenolic OH group. Since the $\text{p}K_1$ and $\text{p}K_2$ values are in the range 3.85–4.82 and 10.34–11.1, respectively, it can be concluded that all the studied compounds are in their neutral HL form at the physiological pH, and become air sensitive only in the basic pH range (pH > 9) when the deprotonation of the phenolic OH group starts.




Fig. 3 (a) UV-visible spectra recorded for **8a** at various pH values. Inset figure shows the measured absorbance values at 312 nm (●) with the fitted values (solid line) (b) concentration distribution curves calculated for **8a**. { $c = 50 \mu\text{M}$; $l = 2 \text{ cm}$; 30% (v/v) DMSO/ H_2O ; $T = 25 \text{ }^\circ\text{C}$; $l = 0.1 \text{ M (KCl)}$ }.

As it is expected, the $\text{p}K_a$ values determined for **2AP** in pure water ($\text{p}K_1 = 4.91$ and $\text{p}K_2 = 9.87$ ⁴⁵) differ somewhat from those obtained in this work using 30% (v/v) DMSO/ H_2O solvent mixture. Namely, the $\text{p}K_a$ of the NH_3^+ group is lower, while that of the phenolic-OH is higher in the presence of the DMSO than in pure water. DMSO has a lower charge neutralization/deprotonation/protonation processes are more favourable in the more apolar medium. Comparing the $\text{p}K_a$ values to each other (Table 2), it can be concluded that the incorporation of **2AP** into the sterane core resulted in an increase in both of the $\text{p}K_a$ values due to the electron-donating effect of the neighbouring B-ring of the sterane core (*c.f.* **2AP** and **4**). Derivatization on the amino group resulted in secondary amines, and the introduction of the benzyl functional group led to lower $\text{p}K_a$

Table 2 Proton dissociation constants ($\text{p}K_a$) of the compounds ($c_L = 10$ or $50 \mu\text{M}$) determined by UV-visible spectrophotometric titrations. ($T = 25 \text{ }^\circ\text{C}$; $l = 0.1 \text{ M (KCl)}$; 30% (v/v) DMSO/ H_2O)

Compound	R	$\text{p}K_a (\text{NH}_3^+_{\text{amino}})$	$\text{p}K_a (\text{OH}_{\text{phenolic}})$	c_L
2AP	— ^a	4.41 ± 0.02	10.36 ± 0.02	$50 \mu\text{M}$
4	H	4.82 ± 0.01	10.63 ± 0.02	$50 \mu\text{M}$
8a	$\text{CH}_2\text{-Ph}$	4.58 ± 0.03	10.44 ± 0.04	$50 \mu\text{M}$
8b	$\text{CH}_2\text{-(p-F)C}_6\text{H}_4$	4.23 ± 0.04	10.36 ± 0.02	$10 \mu\text{M}$
8c	$\text{CH}_2\text{-(p-Cl)C}_6\text{H}_4$	4.34 ± 0.05	~ 10.8	$10 \mu\text{M}$
8d	$\text{CH}_2\text{-(p-Br)C}_6\text{H}_4$	3.94 ± 0.02	~ 11.1	$10 \mu\text{M}$
8e	$\text{CH}_2\text{-(p-CN)C}_6\text{H}_4$	3.85 ± 0.01	~ 11.0	$10 \mu\text{M}$
8g	$\text{CH}_2\text{-(p-CH}_3\text{)C}_6\text{H}_4$	4.75 ± 0.03	10.34 ± 0.05	$50 \mu\text{M}$
8h	$\text{CH}_2\text{-(p-MeO)C}_6\text{H}_4$	4.76 ± 0.03	~ 10.6	$50 \mu\text{M}$

^a Reference compound.

values (*c.f.* **4** and **8a**). The pK_a values of all the other derivatives (**8b–e**, **8g** and **8h**) are compared to those of **8a** as a reference compound. The electron-donating methyl (**8g**) and methoxy substituents (**8h**) slightly increased the pK_a of the amino group, while the electron-withdrawing CN (**8e**) and halo substituents (**8b–d**) decreased it according to the expectations. Notably, the largest effect was observed in the case of the nitrile and bromo substituents. Differences were also observed in the case of the pK_a values of the phenolic OH group. This group is located further away from the benzyl ring, and the influence of substituents on pK_2 needs some explanations. Effect of the CH_3 , MeO and F groups was negligible, while significantly higher pK_2 values were obtained in the case of the other substituents, although these values are more questionable due to the recognized oxidation process. Most probably, the substituent effect can be realized *via* the possible $N\cdots OH$ hydrogen bond between the deprotonated amino group and the phenolic OH, and the electron-withdrawing groups might result in a stronger hydrogen bond leading to the increase of the pK_2 values.

Pharmacological studies of the synthesized compounds

Cytotoxicity of all the synthesized derivatives was tested *in vitro* on cancerous cell lines MCF-7, PC-3, DU145, and HeLa and also on non-cancerous MRC-5 fibroblasts. For the preliminary screen, compounds were applied in 1.5 μM concentration for 72 h, and a heat map (Fig. 4, ESI, Table S1†) was constructed with the mean cytotoxicity values obtained from three independent experiments. The results of the screen indicated that at 1.5 μM concentration, all the compounds, except for **8a**, **8e**, **9a** and **9h** induced cytotoxicity in at least one or in more cancerous cells (PC-3, DU145, and HeLa), but not in non-cancerous MRC-5 fibroblasts, suggesting that most of the synthesized compounds exhibit a cancer cell-selective toxic feature. Interestingly, none of the compounds showed cytotoxicity on MCF-7 breast cancer cells. These cancer cells lack caspase-3,⁴⁶ a crucial cellular

Table 3 IC_{50} ($\pm SD$) values of some selected estrane-based derivatives and of cisplatin assessed on non-cancerous MRC-5 cells as well as on HeLa and DU145 cancer cell lines

Compound	IC_{50} (μM) $\pm SD$		
	MRC-5	HeLa	DU145
2	$>2.5 \pm 1.35$	1.1 ± 1.01	—
5	$>2.5 \pm 1.41$	0.09 ± 1.39	0.7 ± 1.01
7	$>2.5 \pm 1.02$	1.2 ± 1.01	—
8c	$>2.5 \pm 1.02$	—	1.1 ± 1.01
9b	$>2.5 \pm 1.09$	—	1.2 ± 1.01
Cisplatin	31.8 ± 1.09	347.3 ± 1.08	117.8 ± 1.02

enzyme required to orchestrate programmed cell death.⁴⁷ The observed findings imply that the toxicity induced by these compounds might depend on functional caspase-3, however, further studies are required to prove this notion.

Based on the data of the overall toxicity screen, we selected some derivatives that induced the strongest toxic effects in one or more cancer cell lines. Therefore, we chose compounds **5**, **8c** and **9b** to be tested further on DU145, compounds **2**, **5**, and **7** for a more profound examination on HeLa, and finally, all the aforementioned molecules (namely **2**, **5**, **7**, **8c** and **9b**) were examined on MRC-5 cells to assess their IC_{50} values. Since none of these molecules showed cytotoxicity in MCF-7 breast cancer cells, and only two of them were slightly effective on PC-3 prostate cancer cells, these cell lines were omitted from further analyses.

For IC_{50} determination, the selected steroids or cisplatin (positive control) were applied at different concentrations on the cell lines, and at the end of the treatments cell viability was measured *via* MTT assay. Dose-response curves were fitted on the obtained viability data (ESI, Fig. S1†), and subsequently the corresponding IC_{50} values were calculated (Table 3).

In agreement with the preliminary screen, all the tested compounds, notably, 2-nitroestrone (**2**), the A-ring-fused 2-oxazolones (**5**, **7**), the secondary aminoestradiol **8c** and also the A-ring-fused-N-substituted 2-oxazolone **9b** were effective on cancerous cells at several fold lower concentrations (Table 3, Fig. S1 and S2†) compared to positive control cisplatin.

Unlike the tested steroid derivatives, cisplatin did not show any cancer cell specific cytotoxicity, which implies a potential advantage of these compounds as candidates for future therapeutic developments. The most potent molecule on HeLa cells proved to be the A-ring-fused 2-oxazolone (**5**), whereas the secondary aminoestradiol **8c** and the benzoxazolone **9b** were the most effective agents on DU145 prostate cancer cells despite being ineffective on HeLa cells. It is noteworthy that compound **8c** exerted the strongest effect also on the other prostate cancer cell line PC-3.

Conclusions

In summary, we developed an efficient methodology for the mononitration of estrone at C-2 and C-4 positions. Reduction of nitroestrones by *in situ* generated hydrogen under catalytic conditions resulted in 2- and 4-aminoestradiol derivatives in




Fig. 4 The primary cytotoxic effect of the synthesized aminoestradiols and benzoxazolones on various human cancerous cell lines and on non-cancerous MRC-5 fibroblasts shown on a heat map ($c = 1.5 \mu M$; 72 h incubation time). Control represents the viability of untreated cells.

a single step. Primary and secondary aminoestradiols, the latter obtained by reductive amination of benzaldehyde and *p*-substituted arylaldehydes with 2-aminoestradiol, were subjected to cyclization with CDI to afford A-ring-integrated estradiol-benzoxazolone hybrids in good to excellent yields.

Compounds **4**, **8a–h** were characterized by two pK_a values that belong to the amino (pK_1) and the phenolic-OH (pK_2) moieties, respectively. Based on the determined values ($pK_1 = 3.9\text{--}4.8$; $pK_2 = 10.3\text{--}11.1$), all the studied compounds are present in their neutral form in a wide pH range, including the physiological pH. These aminophenol derivatives become air-sensitive as the deprotonation of the OH functional group starts, thus in the basic pH range ($\text{pH} > 9$). The substituents on the benzyl function of the secondary amines (**8**) have an impact on the proton dissociation processes mainly of the amino group, namely, the electron-donating CH_3 and MeO groups increase pK_1 , while CN and the halogens decrease it.

Based on a preliminary cytotoxicity screen indicating a possible cancer cell-selective pharmacological effect of the synthesized compounds, the 5 most potent agents – A-ring-fused 2-oxazolones (**5**, **7**), the 2-nitroestrone (**2**), the secondary aminoestradiol **8c** and also the A-ring-fused-*N*-substituted 2-oxazolone **9b** – were selected for more thorough testing. The chosen derivatives were effective at lower concentrations on HeLa and DU145 cancerous cells than cisplatin, highlighting their potential as lead compounds for anticancer drug development.

Experimental

Materials and methods

Chemicals, reagents, and solvents were purchased from commercial suppliers (Sigma-Aldrich and Alfa Aesar) and used without further purification. Melting points (Mp) were determined on an SRS Optimelt digital apparatus and are uncorrected. The transformations were monitored by TLC using 0.25 mm thick Kieselgel-G plates (Si 254 F, Merck). The compound spots were detected by spraying with 5% phosphomolybdic acid in 50% aqueous phosphoric acid. Flash chromatographic purifications were carried out on silica gel 60, 40–63 μm (Merck). NMR spectra were recorded with a Bruker DRX 500 instrument at room temperature in CDCl_3 or $\text{DMSO-}d_6$ using residual solvent signals as an internal reference. Chemical shifts are reported in ppm (δ scale), and coupling constants (J) are given in Hz. Multiplicities of the ^1H signals are indicated as a singlet (s), a doublet (d), doublet of doublets (dd), doublet of triplets (dt) a triplet (t), triplet of doublets (td), or a multiplet (m). ^{13}C NMR spectra are ^1H -decoupled and the J-MOD pulse sequence was used for multiplicity editing. In this spin-echo type experiment, the signal intensity is modulated by the different coupling constants J of carbons depending on the number of attached protons. Both protonated and unprotonated carbons can be detected (CH_3 and CH carbons appear as positive signals, while CH_2 and C carbons as negative signals). ESI-HRMS spectra were recorded on a Q Exactive Plus hybrid quadrupole-orbitrap mass spectrometer (Thermo Scientific) equipped with a heated electrospray ionization (HESI-II) probe

that was used in positive and negative ion mode. Samples introduced with FIA (flow injection analysis) method, eluent stream (water, acetonitrile in 1 : 1 volume ratio with 0.1% formic acid) was provided by a Waters Acquity I-class liquid chromatograph (Waters).

Synthetic procedures

Nitration of estrone (1). To a solution of estrone (**1**, 5.41 g, 20 mmol) in CH_2Cl_2 (540 mL), nitric acid (6% (m/m), 15.4 mL, 1 equiv.) was added dropwise and the reaction mixture was heated at reflux temperature for 1 h, after which TLC monitoring indicated the completion of the reaction and the formation of two new products (**2** and **3**). The solvent was removed *in vacuo*, and the remaining crude product was purified by column chromatography on silica gel (eluent: EtOAc/ $\text{CH}_2\text{Cl}_2 = 2 : 98$).

2-Nitroestra-1,3,5(10)-triene-17-one (2). Yield: 3.03 mg (48%); bright yellow crystals; Mp 258–260 $^\circ\text{C}$; ESI-HRMS: m/z 314.1394 [M^-], 314.1398 calcd for $\text{C}_{18}\text{H}_{21}\text{NO}_4$; ^1H NMR (500 MHz, CDCl_3): δ 0.91 (3H, s, 18- CH_3), 1.39–1.69 (6H, m), 1.96–2.10 (3H, m), 2.15 (1H, dt, J 18.9, 8.9), 2.18–2.27 (1H, m), 2.38–2.46 (1H, m), 2.51 (1H, m), 2.85–3.02 (2H, m, 6- H_2), 6.86 (1H, d, J 1.1, 4-H), 7.97 (1H, d, J 1.5, 1-H), 10.40 (1H, s, 3-OH); ^{13}C NMR (125 MHz, CDCl_3): δ 13.9 (18- CH_3), 21.7 (CH_2), 25.8 (CH_2), 26.0 (CH_2), 29.7 (CH_2), 31.4 (CH_2), 35.9 (CH_2), 37.8 (8-CH), 43.6 (9-CH), 47.9 (13-C), 50.5 (14-CH), 119.1 (4-CH), 121.7 (1-CH), 131.9 (2-C), 133.2 (10-C), 148.9 (5-C), 153.0 (3-C), 220.3 (17-C).

4-Nitroestra-1,3,5(10)-triene-17-one (3). Yield: 2.86 g (45%); yellowish white powder; Mp 165–166 $^\circ\text{C}$; ESI-HRMS: m/z 314.1394 [M^-], 314.1398 calcd for $\text{C}_{18}\text{H}_{21}\text{NO}_4$; ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ 0.83 (3H, s, 18- CH_3), 1.28–1.45 (3H, m), 1.42–1.62 (3H, m), 1.71–1.82 (1H, m), 1.95 (2H, m), 2.06 (1H, dt, J 18.9, 8.8), 2.19 (1H, td, J 10.4, 4.7), 2.28–2.39 (1H, m), 2.39–2.48 (1H, m), 2.61 (1H, m), 2.70 (1H, m), 6.86 (1H, d, J 8.6, 2-H), 7.30 (1H, d, J 8.7, 1-H), 10.45 (1H, s, 3-OH); ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$): δ 13.4 (18- CH_3), 20.9 (CH_2), 23.4 (CH_2), 24.8 (CH_2), 25.4 (CH_2), 31.1 (CH_2), 35.2 (CH_2), 36.9 (8-CH), 43.1 (9-CH), 47.1 (13-C), 49.2 (14-CH), 114.4 (2-CH), 127.8 (5-C), 127.8 (1-CH), 131.1 (10-C), 140.3 (4-C), 146.3 (3-C), 219.2 (17-C).

Reduction of nitroestrone derivatives. 2- (**2**) or 4-nitroestrone (**3**) (1.89 g, 6 mmol) was dissolved in MeOH/THF = 1 : 1 (100 mL) and cooled to 0 $^\circ\text{C}$, followed by the addition of 10% Pd-C (200 mg). To this suspension, NaBH_4 (0.91 g, 24 mmol, 4 equiv.) was added in small portions. After 30 min, TLC indicated complete conversion, so the solution was neutralized with diluted HCl, filtered through a Cellite® pad for the removal of the Pd-C catalyst, and the solvent was evaporated under reduced pressure. To the crude product MeOH (20 mL) was added, and the solution was poured onto ice-cold water. The forming white precipitate was filtered off, washed with water, and dried.

2-Aminoestra-1,3,5(10)-triene-3,17 β -diol (4). Substrate: **2**, yield: 1.78 g, (97%, white solid); Mp 188–190 $^\circ\text{C}$, ESI-HRMS: m/z 288.1969 [$\text{M} + \text{H}$] $^+$, 288.1958 calcd for $\text{C}_{18}\text{H}_{25}\text{NO}_2$; ^1H NMR (500 MHz, $\text{DMSO-}d_6$): δ 0.67 (3H, s, 18- CH_3), 1.03–1.36 (6H, m), 1.38 (1H, m), 1.52–1.62 (1H, m), 1.74 (1H, m), 1.79–1.86 (1H, m),

1.83–1.93 (1H, m), 2.01 (1H, s), 2.13 (1H, dt, *J* 12.1, 3.3), 2.55 (1H, dt, *J* 10.3, 5.1), 2.61 (1H, m), 3.52 (1H, td, *J* 8.5, 4.6, 17 α -H), 4.15 (2H, s, 2-NH₂), 4.39 (1H, d, *J* 4.8, 17-OH), 6.32 (1H, s, 1 H), 6.52 (1H, s, 4 H), 8.52 (1H, s, 3-OH); ¹³C NMR (125 MHz, DMSO-*d*₆): δ 11.1 (18-CH₃), 22.7 (CH₂), 26.2 (CH₂), 27.3 (CH₂), 28.3 (CH₂), 29.9 (CH₂), 36.6 (CH₂), 38.8 (8-CH), 42.7 (C-13), 43.7 (9-CH), 49.6 (14-CH), 80.0 (17-CH), 111.6 (4-CH), 114.4 (1-CH), 123.8 (5-C), 130.5 (2-C), 133.8 (10-C), 142.0 (3-C).

4-Aminoestra-1,3,5(10)-triene-3,17 β -diol (6). Substrate: **3**, yield: 1.68 g, (92%, brownish solid); the product was subjected to ring-closure directly after formation without characterization.

General procedure for the synthesis of secondary aminoestradiols (8a–h)

To a solution of 2-aminoestradiol (**4**, 287 mg, 1 mmol) in MeOH (5 mL), catalytic amount of AcOH and molecular sieves were added, followed by the addition of (*p*-substituted) benzaldehyde (1.1 equiv.). The mixture was kept at reflux temperature for 1 h, cooled to room temperature and reduced with NaBH₄ (76 mg, 2 equiv.). After complete conversion of the Schiff-base (30 min, TLC), the reaction was quenched with water, MeOH was removed, and the remaining residue was extracted with EtOAc (3 \times 5 mL). The combined organic phase was washed with water and brine, dried over Na₂SO₄, and concentrated *in vacuo*. The crude product was purified by column chromatography using EtOAc/CH₂Cl₂ (5 : 95) as eluent.

2-(Benzylamino)estra-1,3,5(10)-triene-3,17 β -diol (8a). The synthesis was carried out according to the general procedure, using benzaldehyde (110 μ L, 117 mg). Yield: 286 mg (76%); white solid; Mp 171–173 °C; ESI-HRMS: *m/z* 378.2440 [M + H]⁺, 378.2428 calcd for C₂₅H₃₂NO₂⁺; ¹H NMR (500 MHz, DMSO-*d*₆): δ 0.63 (3H, s, 18-CH₃), 0.99–1.29 (6H, m), 1.36 (1H, m), 1.55 (1H, m), 1.75 (2H, m), 1.86 (1H, m), 1.97 (1H, td, *J* 10.7, 4.0), 2.04 (1H, dt, *J* 10.7, 3.4), 2.55 (1H, dd, *J* 6.1, 2.1), 2.60 (1H, m), 3.49 (1H, td, *J* 8.5, 4.5, 17 α -H), 4.26 (2H, d, *J* 5.3, N-CH₂), 4.38 (1H, d, *J* 4.8, 17-OH), 4.85 (1H, t, *J* 6.2, -NH), 6.35 (2H, d, *J* 5.0, 1 H, 4 H), 7.18–7.25 (1H, m, 4'-H), 7.27–7.37 (4H, m, 2'-H, 3'-H, 5'-H, 6'-H), 8.86 (1H, s, 3-OH); ¹³C NMR (125 MHz, DMSO-*d*₆): δ 11.1 (18-CH₃), 22.7 (CH₂), 26.0 (CH₂), 27.2 (CH₂), 28.3 (CH₂), 29.9 (CH₂), 36.6 (CH₂), 38.8 (8-CH), 42.7 (13-C), 43.8 (9-CH), 47.0 (N-CH₂), 49.5 (14-CH), 80.0 (17-CH), 107.5 (4-CH), 113.7 (1-CH), 123.1 (5-C), 126.4 (4'-C), 127.1 (2'-CH and 6'-CH), 128.1 (3'-CH and 5'-CH), 130.3 (10-C), 134.8 (2-C), 140.7 (1'-C), 142.1 (3-C).

2-(4'-Fluorobenzylamino)estra-1,3,5(10)-triene-3,17 β -diol (8b). The synthesis was carried out according to the general procedure, using *p*-fluorobenzaldehyde (118 μ L, 137 mg). Yield: 301 mg (76%); orange solid; Mp 163–165 °C; ESI-MS: *m/z* 396.2341 [M + H]⁺, 396.2333 calcd for C₂₅H₃₁FNO₂⁺; ¹H NMR (500 MHz, DMSO-*d*₆): δ 0.63 (3H, s, 18-CH₃), 1.01–1.27 (6H, m), 1.31–1.42 (1H, m), 1.55 (1H, m), 1.69–1.92 (3H, m), 1.97 (1H, td, *J* 10.3, 3.6), 2.04 (1H, dd, *J* 12.8, 4.1), 2.52–2.64 (2H, m), 3.49 (1H, td, *J* 8.5, 4.7, 17 α -H), 4.22–4.27 (2H, m, N-CH₂), 4.38 (1H, d, *J* 4.8, 17-OH), 4.90 (1H, s, -NH), 6.33 (2H, d, *J* 7.5, 1-H and 4-H), 7.11 (2H, t, *J* 8.9, 7.6, 3'-H and 5'-H), 7.37 (2H, dd, *J* 8.5, 2'-H and 6'-H), 8.85 (1H, s, 3-OH); ¹³C NMR (125 MHz, DMSO-*d*₆): δ 11.1 (18-CH₃), 22.7 (CH₂), 26.0 (CH₂), 27.2 (CH₂), 28.3 (CH₂), 29.9 (CH₂),

36.6 (CH₂), 38.8 (8-CH), 42.7 (13-C), 43.8 (9-CH), 46.2 (N-CH₂), 49.5 (14-CH), 80.0 (17-CH), 107.6 (1-CH), 113.7 (4-CH), 114.7, 114.8, 123.2 (5-C), 128.9 (CH), 128.9 (CH), 130.3 (10-C), 134.6 (2-C), 136.8, 136.9, 142.1 (3-C), 160.0, 161.9.

2-(4'-Chlorobenzylamino)estra-1,3,5(10)-triene-3,17 β -diol (8c). The synthesis was carried out according to the general procedure, using *p*-chlorobenzaldehyde (154 mg). Yield: 376 mg (91%); yellowish white solid; Mp 180–183 °C; ESI-HRMS: *m/z* 412.2049 [M + H]⁺, 412.2038 calcd for C₂₅H₃₁ClNO₂⁺; ¹H NMR (500 MHz, DMSO-*d*₆): δ 0.62 (3H, s, 18-CH₃), 1.00–1.28 (6H, m), 1.30–1.41 (1H, m), 1.54 (1H, m), 1.67–1.74 (1H, m), 1.74–1.80 (1H, m), 1.86 (1H, m), 1.91–2.06 (2H, m), 2.51–2.65 (2H, m), 3.48 (1H, td, *J* 8.5, 4.7, 17 α -H), 4.25 (2H, d, *J* 5.7, N-CH₂), 4.43 (1H, d, *J* 4.8, 17-OH), 5.02 (1H, t, *J* 6.3, -NH), 6.28 (1H, s, 1 H), 6.33 (1H, s, 4 H), 7.35 (4H, s, 2'-H, 3'-H, 5'-H and 6'-H), 8.92 (1H, s, 3-OH); ¹³C NMR (125 MHz, DMSO-*d*₆): δ 11.2 (18-CH₃), 22.7 (CH₂), 26.1 (CH₂), 27.2 (CH₂), 28.4 (CH₂), 29.9 (CH₂), 36.6 (CH₂), 38.8 (8-CH), 42.8 (13-C), 43.9 (9-CH), 46.1 (N-CH₂), 49.5 (14-CH), 80.0 (17-CH), 107.5 (1-CH), 113.7 (4-CH), 123.3 (5-C), 128.1 (3'-CH and 5'-CH), 128.9 (2'-CH and 6'-CH), 130.3 (4'-C), 130.9 (10-C), 134.5 (2-C), 140.0 (1'-C), 142.2 (3-C).

2-(4'-Bromobenzylamino)estra-1,3,5(10)-triene-3,17 β -diol (8d). The synthesis was carried out according to the general procedure, using *p*-bromobenzaldehyde (204 mg). Yield: 342 mg (75%); white solid; Mp 172–175 °C; ESI-MS: *m/z* 456.1542 [M + H]⁺, 456.1533 calcd for C₂₅H₃₁BrNO₂⁺; ¹H NMR (500 MHz, DMSO-*d*₆): δ 0.63 (3H, s, 18-CH₃), 1.00–1.09 (1H, m), 1.11–1.27 (5H, m), 1.36 (1H, m), 1.55 (1H, m), 1.68–1.78 (1H, m), 1.75–1.81 (1H, m), 1.86 (1H, m), 1.92–2.06 (2H, m), 2.52–2.64 (2H, m), 3.49 (1H, td, *J* 8.5, 4.8, 17 α -H), 4.24 (2H, d, *J* 5.5, N-CH₂), 4.38 (1H, d, *J* 4.8, 17-OH), 4.98 (1H, t, *J* 6.4, -NH), 6.29 (1H, s, 1-H), 6.34 (1H, s, 4-H), 7.30 (2H, d, *J* 8.3, 2'-H and 6'-H), 7.48 (2H, d, *J* 8.3, 3'-H and 5'-H), 8.86 (1H, s, 3-OH); ¹³C NMR (125 MHz, DMSO-*d*₆): δ 11.1 (18-CH₃), 22.7 (CH₂), 26.0 (CH₂), 27.1 (CH₂), 28.3 (CH₂), 29.9 (CH₂), 36.6 (CH₂), 38.8 (8-CH), 42.7 (13-C), 43.8 (9-CH), 46.2 (N-CH₂), 49.5 (14-CH), 80.0 (17-CH), 107.5 (1-CH), 113.7 (4-CH), 119.2 (4'-C), 123.3 (5 C), 129.3 (2'-CH and 6'-CH), 130.3 (10 C), 130.9 (3'-CH and 5'-CH), 134.5 (2-C), 140.4 (3-C), 142.2 (1'-C).

2-(4'-Cyanobenzylamino)estra-1,3,5(10)-triene-3,17 β -diol (8e). The synthesis was carried out according to the general procedure, using *p*-cyanobenzaldehyde (144 mg). Yield: 386 mg (96%); white solid; Mp 184–187 °C; ESI-HRMS: *m/z* 403.2391 [M + H]⁺, 403.2380 calcd for C₂₆H₃₁N₂O₂⁺; ¹H NMR (500 MHz, DMSO-*d*₆): δ 0.61 (3H, s, 18-CH₃), 0.99–1.35 (7H, m), 1.32–1.40 (1H, m), 1.54 (1H, m), 1.67–1.78 (1H, m), 1.85 (1H, m), 1.89–2.04 (2H, m), 2.51–2.64 (2H, m), 3.48 (1H, td, *J* 8.5, 4.7, 17 α -H), 4.37 (2H, d, *J* 6.0, N-CH₂), 4.42 (1H, d, *J* 4.8, 17-OH), 5.21 (1H, t, *J* 6.4, -NH), 6.21 (1H, s, 1-H), 6.34 (1H, s, 4-H), 7.52 (2H, d, *J* 8.0, 2'-H and 6'-H), 7.76 (2H, d, *J* 8.3, 3'-H and 5'-H), 8.96 (1H, s, 3-OH); ¹³C NMR (125 MHz, DMSO-*d*₆): δ 11.2 (18-CH₃), 22.7 (CH₂), 26.0 (CH₂), 27.2 (CH₂), 28.4 (CH₂), 29.9 (CH₂), 36.6 (CH₂), 38.8 (8-CH), 42.7 (13-C), 43.8 (9-CH), 46.4 (N-CH₂), 49.5 (14-CH), 80.0 (17-CH), 107.5 (1-CH), 109.1 (4'-C), 113.8 (4-CH), 119.0 (4'-CN), 123.4 (5-C), 127.9 (2'-CH and 6'-CH), 130.3 (10-C), 132.1 (3'-CH and 5'-CH), 134.3 (2-C), 142.3 (3-C), 147.4 (1'-C).

2-(4'-Nitrobenzylamino)estra-1,3,5(10)-triene-3,17 β -diol (8f). The synthesis was carried out according to the general

procedure, using *p*-nitrobenzaldehyde (166 mg). Yield: 346 mg (82%); yellow solid. Due to stability issues it was immediately converted into **9f** without purification.

2-(4'-Methylbenzylamino)estra-1,3,5(10)-triene-3,17β-diol (8g). The synthesis was carried out according to the general procedure, using *p*-tolualdehyde (132 mg). Yield: 346 mg (72%); white solid; Mp 151–153 °C; ESI-HRMS: m/z 392.2596 $[M + H]^+$, 392.2584 calcd for $C_{26}H_{34}NO_2^+$; 1H NMR (500 MHz, DMSO- d_6): δ 0.64 (3H, s, 18-CH₃), 1.06–1.24 (6H, m), 1.31–1.42 (1H, m), 1.55 (1H, m), 1.69–1.76 (1H, m), 1.79 (1H, dt, J 12.3, 3.1), 1.87 (1H, m), 1.93–2.02 (1H, m), 2.04–2.11 (1H, m), 2.27 (3H, s), 2.47–2.66 (2H, m), 3.50 (1H, td, J 8.5, 4.3, 17 α -H), 4.20 (2H, s, N-CH₂), 4.38 (1H, d, J 4.8, -NH), 4.77 (1H, s, 17-OH), 6.33 (1H, s, 1-H), 6.37 (1H, s, 4-H), 7.11 (2H, d, J 7.8, 3'-H and 5'-H), 7.23 (2H, d, J 8.0, 2'-H and 6'-H), 8.83 (1H, s, 3-OH); ^{13}C NMR (125 MHz, DMSO- d_6): δ 11.1 (18-CH₃), 20.5 (CH₂), 22.7 (CH₂), 26.1 (CH₂), 27.2 (CH₂), 28.3 (CH₂), 29.9 (CH₂), 36.6 (CH₂), 38.8 (8-CH), 42.7 (13-C), 43.8 (9-CH), 46.8 (N-CH₂), 49.5 (14-CH), 80.0 (17-CH), 107.5 (1-CH), 113.6 (4-CH), 123.1 (4'-C), 127.1 (3'-CH and 5'-CH), 128.6 (2'-CH and 6'-CH), 130.3 (5-C), 134.80 (1'-C), 135.4 (10-C), 137.5 (2-C), 142.1 (3-C).

2-(4'-Methoxybenzylamino)estra-1,3,5(10)-triene-3,17β-diol (8h). The synthesis was carried out according to the general procedure, using *p*-anisaldehyde (134 μ L, 150 mg). Yield: 384 mg (94%); white solid; Mp 135–137 °C; ESI-HRMS: m/z 408.2551 $[M + H]^+$, 408.2533 calcd for $C_{26}H_{34}NO_3^+$; 1H NMR (500 MHz, DMSO- d_6): δ 0.64 (3H, s, 18-CH₃), 0.99–1.28 (6H, m), 1.36 (1H, m), 1.50–1.61 (1H, m), 1.68–1.92 (3H, m), 1.98 (1H, td, J 10.8, 4.0), 2.05–2.12 (1H, m), 2.57 (2H, m), 3.49 (1H, td, J 8.5, 4.7, 17 α -H), 3.72 (3H, s, 4'-OMe), 4.17 (2H, d, J 6.0, N-CH₂), 4.43 (1H, d, J 5.1, -NH), 4.75 (1H, t, J 6.2, 17-OH), 6.32 (1H, s, 1-H), 6.36 (1H, s, 4-H), 6.83–6.90 (2H, m, 3'-H and 5'-H), 7.23–7.28 (2H, m, 2'-H and 6'-H), 8.88 (1H, s, 3-OH); ^{13}C NMR (125 MHz, DMSO- d_6): δ 11.2 (18-CH₃), 22.8 (CH₂), 26.1 (CH₂), 27.3 (CH₂), 28.4 (CH₂), 29.9 (CH₂), 36.7 (CH₂), 38.8 (8-CH), 42.8 (13-C), 43.9 (9-CH), 46.5 (N-CH₂), 49.5 (14-CH), 55.0 (4'-OMe), 80.0 (17-CH), 107.6 (CH), 113.6 (3'-CH and 5'-CH), 123.1 (5-C), 128.4 (2'-CH and 6'-CH), 130.3 (1'-C), 132.5 (10-C), 134.8 (2-C), 142.2 (3-C), 158.0 (4'-C).

General procedure for the synthesis of oxazolone hybrids (5, 7 and 9a–h)

The primary (**4** or **6**) or secondary amine (**8a–h**) (0.5 mmol) was dissolved in THF/CH₂Cl₂ = 1 : 4 (5 mL), CDI (89 mg, 1.1 equiv.) and TEA (140 μ L, 1 mmol, 2 eq.) were added and the mixture was kept at reflux temperature for 2 h. The solvent was removed under reduced pressure, the crude product was suspended in water (5 mL), acidified with diluted HCl and extracted with EtOAc (3 \times 5 mL). The combined organic phase was washed with water and brine, dried over anhydrous Na₂SO₄ and concentrated *in vacuo*. The product was purified by column chromatography.

Oxazolo[4',5':2,3]estra-1,3,5(10)-triene-17β-ol-2'-one (5). Substrate: **4** (144 mg); eluent: EtOAc/CH₂Cl₂ = 50 : 50; yield: 120 mg (76%); white powder; Mp 280–282 °C; ESI-HRMS: m/z 314.1761 $[M + H]^+$, 314.1751 calcd for $C_{19}H_{24}NO_3^+$; 1H NMR (500 MHz,

DMSO- d_6): δ 0.67 (3H, s), 1.06–1.45 (7H, m), 1.58 (1H, m), 1.79 (1H, m), 1.88 (2H, m), 2.16 (1H, td, J 10.9, 4.2), 2.23 (1H, dt, J 12.9, 3.6), 2.80 (2H, dt, J 8.1, 4.1, 6-H₂), 3.52 (1H, t, J 8.5, 17 α -H), 4.45 (1H, s, 17-OH), 6.92 (2H, d, J 7.4, 1-H and 4 H), 11.32 (1H, s, NH). ^{13}C NMR (125 MHz, DMSO- d_6): δ 11.1 (18-CH₃), 22.7 (CH₂), 26.1 (CH₂), 26.6 (CH₂), 29.0 (CH₂), 29.8 (CH₂), 36.5 (CH₂), 38.2 (8-CH), 42.7 (13-C), 43.8 (9-CH), 49.6 (14-CH), 79.9 (17-CH), 106.2 (CH), 109.1 (CH), 128.2, 130.0, 135.6, 141.5, 154.6 (2'-C).

Oxazolo[4',5':4,3]estra-1,3,5(10)-triene-17β-ol-2'-one (7). Substrate: **6** (144 mg); eluent: EtOAc/CH₂Cl₂ = 50 : 50; yield: 105 mg (67%); white powder; Mp 258–260 °C; ESI-HRMS: m/z 314.1757 $[M + H]^+$, 314.1751 calcd for $C_{19}H_{24}NO_3^+$; 1H NMR (500 MHz, DMSO- d_6): δ 0.67 (3H, s, 18-CH₃), 1.07–1.44 (7H, m), 1.60 (1H, m), 1.88 (3H, m), 2.17 (1H, td, J 11.1, 4.3), 2.29 (1H, m), 2.59–2.70 (1H, m), 2.73–2.81 (1H, m), 3.53 (1H, td, J 8.5, 4.3, 17 α -H), 4.43 (1H, d, J 4.8, 17-OH), 7.00 (2H, s, 1-H and 4-H), 11.44 (1H, s, NH); ^{13}C NMR (125 MHz, DMSO- d_6): δ 11.1 (18-CH₃), 22.7 (CH₂), 24.1 (CH₂), 25.8 (CH₂), 26.2 (CH₂), 29.8 (CH₂), 36.5 (CH₂), 38.0 (8-CH), 42.6 (13-C), 43.6 (9-CH), 49.4 (14-CH), 79.9 (17-CH), 106.3 (2-CH), 118.3 (1-CH), 119.1 (5-C), 128.4 (4-C), 135.7 (3-C), 140.8 (10-C), 154.9 (2'-C).

3'-Benzylloxazolo[4',5':2,3]estra-1,3,5(10)-triene-17β-ol-2'-one (9a). Substrate: **8a** (189 mg); eluent: EtOAc/CH₂Cl₂ = 5 : 95; yield: 139 mg (69%); white powder; Mp 148–150 °C; ESI-HRMS: m/z 404.2228 $[M + H]^+$, 404.2220 calcd for $C_{26}H_{30}NO_3^+$; 1H NMR (500 MHz, CDCl₃): δ 0.77 (3H, s), 1.17 (1H, m), 1.23–1.54 (7H, m), 1.70 (1H, m), 1.88 (1H, m), 1.94 (1H, m), 2.06–2.23 (3H, m), 2.79–2.94 (2H, m), 3.72 (1H, t, J 8.5, 17 α -H), 4.90–5.03 (2H, m, N-CH₂), 6.75 (1H, s, 1-H), 6.91 (1H, s, 4-H), 7.31 (1H, dt, 4''-CH), 7.31–7.39 (4H, m, 2''-H, 3''-H, 5''-H and 6''-H); ^{13}C NMR (125 MHz, CDCl₃): δ 11.2 (18-CH₃), 23.3 (CH₂), 26.7 (CH₂), 27.2 (CH₂), 29.85 (CH₂), 30.8 (CH₂), 36.8 (CH₂), 38.7 (8-CH), 43.3 (13-C), 44.4 (9-CH), 46.2 (N-CH₂), 50.3 (14-CH), 81.9 (17-CH), 105.9 (4-CH), 110.1 (1-CH), 127.8 (3''-CH and 5''-CH), 128.3 (4''-CH), 129.1 (1''-C), 129.1 (2''-CH and 6''-CH), 131.6 (2-C), 135.2 (5-C), 136.4 (10-C), 141.2 (3-C), 155.3 (2'-C).

3'-(4'-Fluorobenzyl)oxazolo[4',5':2,3]estra-1,3,5(10)-triene-17β-ol-2'-one (9b). Substrate: **8b** (198 mg); eluent: EtOAc/CH₂Cl₂ = 5 : 95; yield: 160 mg (76%); white powder; Mp 146–148 °C; ESI-HRMS: m/z 422.2136 $[M + H]^+$, 422.2126 calcd for $C_{26}H_{29}FNO_3^+$; 1H NMR (500 MHz, CDCl₃): δ 0.77 (3H, s, 18-CH₃), 1.13–1.75 (9H, m), 1.88 (1H, m), 1.96 (1H, dt, J 12.2, 2.9), 2.07–2.24 (3H, m), 2.80–2.94 (2H, m), 3.73 (1H, t, J 8.5, 17 α -H), 4.88–4.99 (2H, m, N-CH₂), 6.74 (1H, s, 1-H), 6.91 (1H, s, 4-H), 7.04 (2H, td, J 8.5, 1.4), 7.29–7.38 (2H, m); ^{13}C NMR (125 MHz, CDCl₃): δ 11.2 (18-CH₃), 23.3 (CH₂), 26.7 (CH₂), 27.2 (CH₂), 29.8 (CH₂), 30.8 (CH₂), 36.8 (CH₂), 38.7 (8-CH), 43.3 (13-C), 44.4 (9-CH), 45.4 (N-CH₂), 50.3 (14-CH), 81.9 (17-CH), 105.7 (1-CH), 110.3 (4-CH), 116.0, 116.2, 128.8 (2-C), 129.5, 129.6, 131.0, 131.00, 131.8 (5-C), 136.4, 141.1, 155.2 (2'-C), 161.7, 163.7.

3'-(4'-Chlorobenzyl)oxazolo[4',5':2,3]estra-1,3,5(10)-triene-17β-ol-2'-one (9c). Substrate: **8c** (206 mg); eluent: EtOAc/CH₂Cl₂ = 5 : 95; yield: 205 mg (94%); white powder; Mp 128–130 °C; ESI-HRMS: m/z 438.1840 $[M + H]^+$, 438.1830 calcd for $C_{26}H_{29}ClNO_3^+$; 1H NMR (500 MHz, DMSO- d_6): δ 0.65 (3H, s, 18-CH₃), 1.05–1.43 (7H, m), 1.57 (1H, m), 1.78 (1H, m), 1.87 (2H, m), 2.14 (1H, td, J 11.0, 4.2), 2.28 (1H, m), 2.77–2.83 (2H, m),

3.52 (1H, td, *J* 8.5, 4.9, 17 α -H), 4.47 (1H, d, *J* 4.8, 17-OH), 5.02 (2H, s, N-CH₂), 7.01 (1H, s, 4-H), 7.13 (1H, s, 1-H), 7.36–7.45 (4H, m, 2''-H, 3''-H, 5''-H and 6''-H); ¹³C NMR (125 MHz, DMSO-*d*₆): δ 11.2 (18-CH₃), 22.7 (CH₂), 26.1 (CH₂), 26.6 (CH₂), 29.1 (CH₂), 29.9 (CH₂), 36.5 (CH₂), 38.2 (8-CH), 42.7 (13-C), 44.0 (overlapping, 9-CH and N-CH₂), 49.5 (14-CH), 79.9 (17-CH), 106.2 (1-CH), 109.5 (4-CH), 128.6 (2 C), 128.7 (3''-CH and 5''-CH), 129.4 (2''-CH and 6''-CH), 130.9 (4''-C), 132.4 (5-C), 134.9 (1''-C), 136.0 (10-C), 140.2 (3-C), 154.1 (2'-C).

3'-(4''-Bromobenzyl)oxazolo[4',5':2,3]estra-1,3,5(10)-triene-17 β -ol-2'-one (9d). Substrate: **8d** (228 mg); eluent: EtOAc/CH₂Cl₂ = 5 : 95; yield: 186 mg (77%); white powder; Mp 159–161 °C; ESI-HRMS: *m/z* 482.1335 [M + H]⁺, 482.1325 calcd for C₂₆H₂₉BrNO₃⁺; ¹H NMR (500 MHz, CDCl₃): δ 0.77 (3H, s, 18-CH₃), 1.13–1.54 (8H, m), 1.70 (1H, m), 1.88 (1H, m), 1.96 (1H, m), 2.07–2.24 (3H, m), 2.80–2.94 (2H, m), 3.73 (1H, t, *J* 8.5, 17 α -H), 4.85–4.98 (2H, m), 6.72 (1H, s, 4 H), 6.92 (1H, s, 1-H), 7.22 (2H, s, *J* 8.4, 2''-H and 6''-H), 7.48 (2H, d, *J* 8.4, 3''-H and 5''-H); ¹³C NMR (125 MHz, CDCl₃): δ 11.2 (18-CH₃), 23.3 (CH₂), 26.7 (CH₂), 27.2 (CH₂), 29.9 (CH₂), 30.8 (CH₂), 36.8 (CH₂), 38.6 (8-CH), 43.3 (13-C), 44.4 (9-CH), 45.5 (N-CH₂), 50.3 (14-CH), 81.9 (17-CH), 105.6 (1-CH), 110.3 (4-CH), 122.4 (4''-C), 128.8 (2-C), 129.4 (2''-CH and 6''-CH), 131.9 (5-C), 132.3 (3''-CH and 5''-CH), 134.2 (1''-C), 136.5 (10-C), 141.1 (3-C), 155.2 (2'-C).

3'-(4''-Cyanobenzyl)oxazolo[4',5':2,3]estra-1,3,5(10)-triene-17 β -ol-2'-one (9e). Substrate: **8e** (201 mg); eluent: EtOAc/CH₂Cl₂ = 10 : 90; yield: 197 mg (92%); white powder; Mp 134–137 °C; ESI-HRMS: *m/z* 429.2181 [M + H]⁺, 429.2173 calcd for C₂₇H₂₉N₂O₃⁺; ¹H NMR (500 MHz, DMSO-*d*₆): δ 0.65 (3H, s, 18-CH₃), 1.04–1.43 (7H, m), 1.57 (1H, m), 1.74–1.93 (3H, m), 2.15 (1H, td, *J* 10.9, 4.0), 2.23–2.31 (1H, m), 2.81 (2H, dd, *J* 8.0, 3.9), 3.52 (1H, td, *J* 8.5, 4.8 17 α -H), 4.47 (1H, d, *J* 4.8, 17-OH), 5.14 (2H, s, N-CH₂), 7.04 (1H, s, 4-H), 7.15 (1H, s, 1-H), 7.53 (2H, d, *J* 8.3, 2''-H and 6''-H), 7.83 (2H, d, *J* 8.3, 3''-H and 5''-H); ¹³C NMR (125 MHz, DMSO-*d*₆): δ 11.2 (18-CH₃), 22.7 (CH₂), 26.2 (CH₂), 26.6 (CH₂), 29.1 (CH₂), 29.9 (CH₂), 36.4 (CH₂), 38.2 (8-CH), 42.7 (13-C), 44.0 (9-CH), 44.3 (N-CH₂), 49.5 (14-CH), 79.9 (17-CH), 106.1 (1-CH), 109.5 (4-CH), 110.5 (4''-CN), 118.5 (4''-C), 128.2 (2''-CH and 6''-CH), 128.6 (2-C), 131.0 (5-C), 132.6 (3''-CH and 5''-CH), 136.1 (10-C), 140.2 (3-C), 141.5 (1''-C), 154.1 (2'-C).

3'-(4''-Nitrobenzyl)oxazolo[4',5':2,3]estra-1,3,5(10)-triene-17 β -ol-2'-one (9f). Substrate: **8f** (211 mg); eluent: EtOAc/CH₂Cl₂ = 5 : 95; yield: 206 mg (92%); yellowish white powder; Mp 168–170 °C; ESI-HRMS: *m/z* 449.2082 [M + H]⁺, 449.2071 calcd for C₂₆H₂₉N₂O₅⁺; ¹H NMR (500 MHz, DMSO-*d*₆): δ 0.65 (3H, s, 18-CH₃), 1.06–1.43 (7H, m), 1.58 (1H, m), 1.74–1.93 (3H, m), 2.15 (1H, td, *J* 10.9, 3.9), 2.24–2.32 (1H, m), 2.81 (2H, dd, *J* 8.1, 3.9), 3.51 (1H, td, *J* 8.5, 4.9, 17 α -H), 4.47 (1H, d, *J* 4.8, 17-OH), 5.20 (2H, s, N-CH₂), 7.05 (1H, s, 4-H), 7.17 (1H, s, 1-H), 7.60 (2H, d, *J* 8.8, 2''-H and 6''-H), 8.22 (2H, d, *J* 8.8, 3''-H and 5''-H); ¹³C NMR (125 MHz, DMSO-*d*₆): δ 11.2 (18-CH₃), 22.7 (CH₂), 26.2 (CH₂), 26.6 (CH₂), 29.1 (CH₂), 29.9 (CH₂), 36.4 (CH₂), 38.2 (8-CH), 42.7 (13-C), 44.0 (9-CH), 44.1 (N-CH₂), 49.5 (14-CH), 79.9 (17-CH), 106.2 (1-CH), 109.6 (4-CH), 123.8 (3''-CH and 5''-CH), 128.5 (2''-CH and 6''-CH), 128.6 (2-C), 131.1 (5-C), 136.2 (10-C), 140.2 (3-C), 143.6 (1''-C), 147.0 (4''-C), 154.1 (2'-C).

3'-(4''-Methylbenzyl)oxazolo[4',5':2,3]estra-1,3,5(10)-triene-17 β -ol-2'-one (9g). Substrate: **8g** (196 mg); eluent: EtOAc/

CH₂Cl₂ = 5 : 95; yield: 163 mg (78%); white powder; Mp 129–131 °C; ESI-HRMS: *m/z* 418.2385 [M + H]⁺, 418.2377 calcd for C₂₇H₃₂NO₃⁺; ¹H NMR (500 MHz, DMSO-*d*₆): δ 0.66 (3H, s, 18-CH₃), 1.04–1.47 (7H, m), 1.58 (1H, m), 1.69–1.82 (1H, m), 1.87 (2H, m), 2.15 (1H, td, *J* 11.2, 10.7, 4.0), 2.26 (4H, m), 2.80 (2H, dt, *J* 8.4, 3.6, 6-H₂), 3.52 (1H, td, *J* 8.5, 4.9, 17 α -H), 4.42 (1H, d, *J* 4.8, 17-OH), 4.96 (2H, s, N-CH₂), 7.00 (1H, s, 4-H), 7.09 (1H, s, 1-H), 7.16 (2H, d, *J* 7.8, 3''-H and 5''-H), 7.25 (2H, d, *J* 8.0, 2''-H and 6''-H); ¹³C NMR (125 MHz, DMSO-*d*₆): δ 11.1 (18-CH₃), 20.5 (CH₂), 22.6 (CH₂), 26.1 (CH₂), 26.5 (CH₂), 29.0 (CH₂), 29.8 (CH₂), 36.4 (CH₂), 38.1 (8-CH), 42.6 (13 C), 43.9 (9-CH), 44.5 (N-CH₂), 49.5 (14-CH), 79.9 (17-CH), 106.1 (1-CH), 109.3 (4-CH), 127.4 (2''-CH and 6''-CH), 128.6 (2 C), 129.1 (3''-CH and 5''-CH), 130.7 (1''-C), 132.7 (5 C), 135.9 (4''-C), 136.9 (10-C), 140.1 (3-C), 154.1 (2'-C).

3'-(4''-Methoxybenzyl)oxazolo[4',5':2,3]estra-1,3,5(10)-triene-17 β -ol-2'-one (9h). Substrate: **8h** (204 mg); eluent: EtOAc/CH₂Cl₂ = 2 : 98; yield: 195 mg (90%); white powder; Mp 136–138 °C; ESI-MS: *m/z* 434.2335 [M + H]⁺, 434.2326 calcd for C₂₇H₃₂NO₄⁺; ¹H NMR (500 MHz, DMSO-*d*₆): δ 0.66 (3H, s, 18-CH₃), 1.10–1.43 (7H, m), 1.57 (1H, m), 1.78 (1H, m), 1.87 (2H, m), 2.15 (1H, td, *J* 10.9, 4.0), 2.25–2.33 (1H, m), 2.79 (2H, dt, *J* 8.4, 3.4), 3.52 (1H, td, *J* 8.5, 4.7, 17 α -H), 3.72 (3H, s, 4''-OMe), 4.48 (1H, d, *J* 4.8, 17-OH), 4.94 (2H, s, N-CH₂), 6.91 (2H, d, *J* 8.6, 3''-H and 5''-H), 7.00 (1H, s, 4-H), 7.12 (1H, s, 1-H), 7.32 (2H, d, *J* 8.6, 2''-H and 6''-H); ¹³C NMR (125 MHz, DMSO-*d*₆): δ 11.2 (18-CH₃), 22.7 (CH₂), 26.2 (CH₂), 26.6 (CH₂), 29.1 (CH₂), 29.9 (CH₂), 36.5 (CH₂), 38.2 (8-CH), 42.7 (13-C), 44.0 (9-CH), 44.2 (N-CH₂), 49.5 (14-CH), 55.1 (4''-OMe), 79.9 (17-CH), 106.3 (1-CH), 109.4 (4-CH), 114.1 (3''-CH and 5''-CH), 127.8 (1''-C), 128.6 (2 C), 129.0 (2''-CH and 6''-CH), 130.7 (5-C), 135.9 (10-C), 140.1 (3-C), 154.1 (2'-C), 158.9 (4''-C).

UV-visible spectrophotometric titrations

Stock solutions of tested compounds were prepared in DMSO at 5 mM concentration. UV-visible spectra were recorded for compounds in order to determine proton dissociation constants (*pK_a*) in the pH range 2–12 in a 30% (v/v) DMSO/H₂O mixture at 25.0 ± 0.1 °C. Ionic strength of 0.10 M (KCl) was used in order to keep the activity coefficients constant. The titrations were performed with carbonate-free KOH solution of known concentration (0.10 M) with 30% (v/v) DMSO content. The electrode system was calibrated to the pH = –log[H⁺] scale by means of blank titrations (HCl vs. KOH) according to the method suggested by Irving *et al.*⁴⁸ The average water ionization constant (*pK_w*) is 14.52 ± 0.05 in the 30% (v/v) DMSO/H₂O mixture. Argon was always passed over the solutions during the titrations. An Agilent Cary 8454 diode array spectrophotometer was used to record the UV-visible spectra at an interval of 200–800 nm. The path length was 2 or 5 cm. Spectrophotometric titrations were performed on samples containing the compounds at 10 or 50 μ M concentration. Proton dissociation constants (*K_a*) of the compounds and the UV-visible spectra of the individual species in the differently protonated forms were calculated by the computer program PSEQUAD.⁴⁹

Cell culture

All the cell lines were purchased from ATCC. MCF-7, DU145 and PC-3 cells were maintained in RPMI-1640 (LONZA) complete

medium (10% FBS, 2 mM glutamine and penicillin–streptomycin) at 37 °C and 5% CO₂. HeLa and MRC-5 cells were maintained in EMEM (LONZA) complete medium at 37 °C and 5% CO₂. Treatments were applied in cell specific complete medium described above.

MTT cytotoxicity assay

Each synthesized compound was dissolved in cell culture grade DMSO (Sigma) to a final concentration of 10 mM. Cytotoxicity of these compounds on cancerous (MCF-7, HeLa, DU145, PC-3) and non-cancerous (MRC-5) cell lines was tested using MTT cell viability assay. Briefly, in a 96-well plate cells were seeded at 5000 cells per well density, and were left to grow overnight in 5% CO₂ atmosphere at 37 °C. Cells were incubated for 72 hours at 37 °C under 5% CO₂ with each synthesized compound separately in 1.5 μM concentration upon the primary screen and only with the selected compounds in concentrations 0.5, 1, 1.5, 2 and 2.5 μM for IC₅₀ determination. At the end of treatment, cell viability was measured by MTT assay as described previously.¹⁹ The positive control cisplatin was applied for 24 h in 20, 40, 80, 160, and 330 μM concentrations. Final results were obtained by three independent replicates. GraphPad Prism 7 software was used to perform statistics and to construct the heat map.

Author contributions

Conceptualization, É. F.; É. A. E. and M. K.; chemical synthesis and optimization experiments, F. K.; pharmacological studies, M. K. G. and D. I. A.; UV-visible spectrophotometric titrations, É. A. E.; structural analysis, F. K.; formal analysis and interpretation of data, M. K. G. and D. I. A.; methodology, resources, supervision, É. F.; M. K. and É. A. E.; writing—original draft preparation, F. K.; M. K. G. and D. I. A.; writing—review and editing, É. F.; M. K. and É. A. E. All authors have read and agreed to the published version of the manuscript.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work was supported by National Research, Development and Innovation Office-NKFI (Hungary) through projects FK 124240, GINOP-2.3.2-15-2016-00038, GINOP-2.3.2-15-2016-00035, and Ministry of Human Capacities (Hungary) grant TKP-2020. The New National Excellence Program of the Ministry for Innovation and Technology (ÚNKP-20-5-SZTE-655 for M. K.) and the János Bolyai Research Scholarship of the Hungarian Academy of Sciences (BO/00878/19/8 for M. K.) are gratefully acknowledged.

References

- 1 L. F. Tietze, H. P. Bell and S. Chandrasekhar, *Angew. Chem., Int. Ed.*, 2003, **42**, 3996.
- 2 G. Bérubé, *Expert Opin. Drug Discovery*, 2016, **11**, 281.
- 3 K. Nepali, S. Sharma, M. Sharma, P. M. S. Bedi and K. L. Dhar, *Eur. J. Med. Chem.*, 2014, **77**, 422.
- 4 G. Mehta and V. Singh, *Chem. Soc. Rev.*, 2002, **31**, 324.
- 5 P. Borah and P. Chowdhury, *Curr. Drug Ther.*, 2017, **12**, 3.
- 6 P. Saha, C. Debnath and G. Bérubé, *J. Steroid Biochem. Mol. Biol.*, 2013, **137**, 271.
- 7 A. Gupta, B. Sathish Kumar and A. S. Negi, *J. Steroid Biochem. Mol. Biol.*, 2013, **137**, 242.
- 8 I. Scherlitz-Hofmann, M. Dubs, R. Krieg, B. Schönecker, M. Kluge and D. Sicker, *Helv. Chim. Acta*, 1997, **80**, 2345.
- 9 S. D. Kuduk, F. F. Zheng, L. Sepp-Lorenzino, N. Rosen and S. J. Danishefsky, *Bioorg. Med. Chem. Lett.*, 1999, **9**, 1233.
- 10 L. F. Tietze, G. Schneider, J. Wölfling, T. Nöbel, C. Wulff, I. Schubert and A. Rübeling, *Angew. Chem., Int. Ed.*, 1998, **37**, 2469.
- 11 G. M. Anstead, K. E. Carlson and J. A. Katzenellenbogen, *Steroids*, 1997, **62**, 268.
- 12 É. Frank and G. Schneider, *J. Steroid Biochem. Mol. Biol.*, 2013, **137**, 301.
- 13 R. Dutour, J. Roy, F. Cortés-Benítez, R. Maltais and D. Poirier, *J. Med. Chem.*, 2018, **61**, 9229.
- 14 G. Panchapakesan, V. Dhayalan, N. Dhatchana Moorthy, N. Saranya and A. K. Mohanakrishnan, *Steroids*, 2011, **76**, 1491.
- 15 T. V. Petrasheuskaya, M. A. Kiss, O. Dömötör, T. Holczbauer, N. V. May, G. Spengler, A. Kincses, A. Č. Gašparović, É. Frank and É. A. Enyedy, *New J. Chem.*, 2020, **44**, 12154.
- 16 M. Numazawa, M. Ando, Y. Watari, T. Tominaga, Y. Hayata and A. Yoshimura, *J. Steroid Biochem. Mol. Biol.*, 2005, **96**, 51.
- 17 D. Bandyopadhyay, G. Rivera, J. L. Sanchez, J. Rivera, J. C. Granados, A. M. Guerrero, F.-M. Chang, R. K. Dearth, J. D. Short and B. K. Banik, *Eur. J. Med. Chem.*, 2014, **82**, 574.
- 18 B. Xiao, T.-J. Gong, Z.-J. Liu, J.-H. Liu, D.-F. Luo, J. Xu and L. Liu, *J. Am. Chem. Soc.*, 2011, **133**, 9250.
- 19 B. Molnár, M. K. Gopisetty, D. I. Adamecz, M. Kiricsi and É. Frank, *Molecules*, 2020, **25**, 4039.
- 20 X. Yang, G. Shan and Y. Rao, *Org. Lett.*, 2013, **15**, 2334.
- 21 J. Poupaeert, P. Carato and E. Colacino, *Curr. Med. Chem.*, 2005, **12**, 877.
- 22 M. Smist and H. Kwiecien, *Curr. Org. Synth.*, 2014, **11**, 676.
- 23 S. Bilginer, H. I. Gul, F. S. Erdal, H. Sakagami, S. Levent, I. Gulcin and C. T. Supuran, *J. Enzyme Inhib. Med. Chem.*, 2019, **34**, 1722.
- 24 G. Neef, *Estrogens and Antiestrogens I, Handbook of Experimental Pharmacology*, Springer-Verlag Berlin Heidelberg, 1999, Vol 135/I, ch. 2, p. 21.
- 25 A. Cornelis, P. Laszlo and P. Pennetreau, *J. Org. Chem.*, 1983, **48**, 4771.
- 26 A. Bose, W. P. Sanjoto, S. Villarreal, H. Aguilar and B. K. Banik, *Tetrahedron Lett.*, 2007, **48**, 3945.
- 27 Y. Wang, Z. Zhan, Y. Zhou, M. Lei and L. Hu, *Monatsh. Chem.*, 2018, **149**, 527.
- 28 J.-M. Poirier and C. Vottero, *Tetrahedron*, 1989, **45**, 1415.
- 29 L. W. Lawrence Woo, B. Leblond, A. Purohit and B. V. L. Potter, *Bioorg. Med. Chem.*, 2012, **20**, 2506.

- 30 T. M. Lavalley, V. S. Pribluda, J. Simons, N. Mabjeesh, P. Giannakakou, *US Pat.*, WO 2003073985 A2, 2003.
- 31 P. N. Rao and J. W. Cessac, *Steroids*, 2002, **67**, 1065.
- 32 P. Crabbé, L. A. Maldonado and I. Sánchez, *Tetrahedron*, 1971, **27**, 711.
- 33 A. Loupy and S. Régnier, *Tetrahedron Lett.*, 1999, **40**, 6221.
- 34 N. Ganguly and P. Mondal, *Synthesis*, 2010, 3705.
- 35 G. Wu, P. N. Ibrahim, Y. Zhou, S. Mamo, S. J. Gillette, Y.-L. Zhu, J. Liu, C. Zhang, K. Zhang, D. R. Artis, *US Pat.*, WO 2010129467, A1, 2010.
- 36 M. Armitage, G. Bret, B. M. Choudary, M. Kingswood, M. Loft, S. Moore, S. Smith and M. W. J. Urquhart, *Org. Process Res. Dev.*, 2012, **16**, 1626.
- 37 I. Bacsa, D. Szemerédi, J. Wölfling, G. Schneider, L. Fekete and E. Mernyák, *Beilstein J. Org. Chem.*, 2018, **14**, 998.
- 38 I. Bacsa, R. Jójárt, G. Schneider, J. Wölfling, P. Maróti, B. E. Herman, M. Szécsi and E. Mernyák, *Steroids*, 2015, **104**, 230–236.
- 39 A. V. Joshi, M. Baidoosi, S. Mukhopadhyay and Y. Sasson, *Org. Process Res. Dev.*, 2003, **7**, 95–97.
- 40 Y. A. Mostafa, B. Kralt, P. P. N. Rao and S. D. Taylor, *Bioorg. Med. Chem.*, 2015, **23**, 5681–5692.
- 41 N. Al Soom and T. Thieman, *Int. J. Org. Chem.*, 2016, **6**, 1–11.
- 42 S. I. El-Hout, S. M. El-Sheikh, H. M. A. Hassan, F. A. Harraz, I. A. Ibrahim and E. A. El-Sharkawy, *Appl. Catal., A*, 2015, **503**, 176–185.
- 43 S. C. Mitchell, P. Carmichael and R. Waring, *Kirk-Othmer Encyclopedia of Chemical Technology*, ed. 2003.
- 44 J. Kaizer, R. Csonka and G. Speier, *J. Mol. Catal.*, 2002, **180**, 91–96.
- 45 A. Vaidyan and P. Bhattacharya, *Indian J. Chem.*, 1994, **33**, 103–1007.
- 46 R. U. Janicke, *Breast Cancer Res. Treat.*, 2009, **117**, 219–221.
- 47 A. G. Porter and R. U. Jänicke, *Cell Death Differ.*, 1999, **6**, 99–104.
- 48 H. M. Irving, M. G. Miles and L. D. Petit, *Anal. Chim. Acta*, 1967, **38**, 475–488.
- 49 L. Zékány and I. Nagypál, *Computational Methods for the Determination of Stability Constants*, Plenum Press, New York, 1985.